Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Cinclus Pharma, Audiocast, Q1'26

By Inderes5/13/2026, 8:00 AM
Cinclus Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Christer Ahlberg
00:00 - 16:00

Thank you very much. And hello and welcome to Cinclus Pharma first quarter 2026 earnings call. As you already know, I'm Christer Ahlberg, CEO of Cinclus Pharma. And with me here today, I also have our CFO, Magnus Christensen, and our R&D director, Margit Mahlapuu. We will walk you through the key developments from the first quarter, and thereafter, we will be happy to answer any questions you may have. So let's go in then directly to the presentation. As you know, our lead asset, Linaprazan glurate, is the next-generation PCAB built around one defining property: sustained, around-the-clock acid control that differentiates the substance from both PPIs and the rest of the PCABs, especially in severe erosive GERD, which is our target population. The patient population we are addressing is large and underserved. Approximately 90 million patients worldwide, including 10 million patients from the U.S. and Europe. And these patients do have severe erosive GERD, and a substantial share of them are not adequately healed on today's standard of care, including PCABs. The gap is what makes the specialty-driven commercial opportunity rather than a primary care one. Better healing and better symptom control translate directly into clinical and commercial differentiation. So, that's important for us; our Phase III program, based on the strong Phase II results we generated previously, began last year in October; and our first study, HEEALING 1, has had very good progress; and we will learn more about that later in this presentation. And we are actually approaching full enrollment in this HEEALING 1 study. And we have now good visibility on the timelines with expected topline results in Q4 already in this year. And this will, of course, be a major value catalyst. And as I said, Margit will tell you more about this later during this presentation. Our program is well de-risked at this stage. We have a robust clinical data package and alignment from both FDA and EMA. Our regulatory strategy. And we have a very well-defined CMC plan. The plan is also aligned with the authorities, and PCABs are gaining significant global momentum. Now available in more than 30 countries and increasingly incorporated into treatment guidelines, which is important. Further validating the mechanism of action and expanding the long-term commercial opportunity for Linaprazan glurate, our substance. And we have, as you already know, a license agreement with Zentiva in Europe worth up to €220 million. This cooperation works well. Very well. We also have a license agreement with Sinorda for selected markets in Asia. And in fact, we already have communicated. Linaprazan glurate is now launched in China by its Sinorda partner during Q1. Our Sinorda partner is in China, and now we have an ongoing local reimbursement application. But at the end of last year, we actually received the national reimbursement in China. So that's very positive. And this chart is a slide that makes a short point. This makes a simple but important point. We see how. How well a drug controls gastric acid over a 24-hour day predicts how well it will heal erosive GERD. The relationship is totally linear, as you see. It doesn't matter if we're talking about PPIs or other PCABs, the biomarkers are there and the correlation is there for all of these drugs. This is a central scientific argument for our program. Our acid control is the biomarker that drives healing in this disease. And the more of the day you can keep the gastric pH above four, the greater chances you have to heal the patients. And that is precisely the variable and the differentiation factor that differentiates Linaprazan glurate, how it's positioned, and how we have built and developed the product. These slides illustrate the number of hours that pH in the stomach is below pH four. With different treatment alternatives. You can see the evolution of this on the market here for decades, where you started with the H2 blockers on the top row, showing the acid control in percentage over the 24 hours, meaning pH above four. And in the diagram there, you can see the number of hours where you are below pH four. Below pH four gives you a risk. There is a risk. Each hour you are below. There is a risk that you could get erosions and symptoms based on the acidic content coming up in the esophagus. H2 blockers 16 hours below pH four. There was a major development when PPIs came to the market. You can see the giant leap there. That was the reason why they became so popular and became the best-selling drug in the world. We can now see the pH has another giant leap going into the first generation of PCABs from PPI. And that's the reason why PCABs have become so popular. They improved acid control. But you can see the same giant leap from the first-generation PCABs to our drug, Linaprazan glurate, in the number of hours of improvement. And this is why we believe it can be done again. This is the reason to believe in the effective differentiation and positioning of the product. So we actually now have a product that offers a solution for the disease and helps patients with severe erosive GERD. But if you also look into this clinically, not only from an acid control perspective, we can actually plot the data into this diagram or biomarker diagram that I showed you earlier. And now we have also all the data, all the healing data from both Vonoprazan and now also from Tegoprazan, the second PCAB in the US. What you can see here is that their drug has also been compared to the PPI Lansoprazole. What you can see here is that it's perfectly spot on to the linear correlation here with the Lansoprazole on 63% pH control. And the data shows healing rate of the C and D in eight weeks of 60 to 70%. Tegoprazan just last week presented their healing data with 75% acid control; they delivered approximately 80% healing rate on C and D patients. And previously we already know about Vonoprazan acid control between 65 to 85% and with a healing rate of approximately 90%. As we already have communicated, and what we have seen in our data is that we have acid control of 96%. So it will be very interesting to follow. Now, the topline results from our first pivotal Phase III trial are coming up later this year. So it looks indeed very promising here. So, to summarize the differentiation factors, as it becomes more and more obvious how to promote this product as best in class, you can see the acid control of Linaprazan glurate at 96%, in comparison to PPIs at 40-70%, and first-generation PCABs like Vonoprazan at 63-85% and Tegoprazan now at 75%. We have a very fast onset. We reach full effect after the first dose in an hour. And that is of course important for many different perspectives. And the good acid control gives us a very good effect. We have in our Phase II data in the best cohort there, delivered a 55 percentage points better healing effect in the severe patient in four weeks compared to Lansoprazole. So, a 55 percentage point difference, or delta. And that should be in comparison to what we now see with Vonoprazan and Tegoprazan, and the products that now have ambitions relevant for us, where they have a delta effect of approximately 15 to 20% over 2 to 8 weeks. So this is a huge difference. As you can see, we have more than double the delta compared to what they have. Our ambition is to heal patients in half the time, four weeks instead of eight weeks, which is the standard of this treatment thanks to this fast and great acid control. And of course, we are looking into the symptom relief and delivering superiority there as well, especially focusing on the nighttime symptom, which is something that every second patient is complaining about, especially pain during nighttime. So this is how we're going to differentiate the product. And also, I just wanted to mention things. The financing structure. We finalized during the quarter. So in March, we entered into a long-term structured credit agreement with Claret Capital Partners, Europe's largest independent growth debt fund manager. The total amount is up to €28 million. The financing is divided into a four-tranche structure, a secured loan facility with warrants and convertibles, and is aligned with key clinical and operational milestones in our program. We draw down an initial €8 million tranche, and that's tranche A at signing already in March. This new capital allows us to look beyond the HEEALING 1 readout and to begin the preparatory work for the next pivotal HEEALING 2 trial in parallel, rather than do it sequentially. So, the intention is that we can move efficiently toward our final Phase III milestone while minimizing the dilution of existing shareholders. It also contributes to financing the remaining development and pre-launch activity of Linaprazan glurate. This is an important deal that we have done, and it will be very supportive for the future. Here are the key events in February. We received positive feedback from the EMA on the CMC, the Chemistry, Manufacturing and Controls strategy for Linaprazan glurate. EMA confirmed that our planned CMC approach is well aligned with the requirements from the agency. For the upcoming marketing authorization application, we got similar positive FDA feedback last autumn, and we now have consistent alignment from both EMA in Europe and FDA in the US on our CMC strategy. This is really important also. FDA provided a positive assessment of our non-clinical development plan following a scientific advice meeting. They concluded that based on the current data package, no additional toxicology studies are required ahead of the future NDA submission. This reduces the development risk and contributes to a more time and resource efficient path to the filing. In February. And of course, severe erosive GERD is included in that. And that's of course, GERD is included in that. This confirms that our current Phase III program is considered a sufficient basis for regulatory submission in the US. In addition to the European ones. And as I also just mentioned, we signed a €28 million financing agreement with Claret Capital Partners, of which €8 million is already drawn in March. Also, I just mentioned, our licensee Sinorda and its local partner Huadong have during the quarter launched Linaprazan glurate on the Chinese market, which of course is an important milestone for us. So to conclude, we have continued to take important steps and have strengthened our position in this past quarter. So with that, I will pass it to Margit for Phase III HEEALING 1 study update. Margit. So please go ahead.

Margit Mahlapuu
16:02 - 18:11

Thank you so much. I will give a brief update on enrollment of subjects in our Phase III ongoing study. In HEEALING 1, and generally, patient inclusion has followed our projections throughout the trial. You can see the development of screened patients on the right side of the slide. Currently, we have about 85% of study patients screened, and more than two thirds of study participants have been randomized to the treatment. And, given this improved screening pace, We can also confidently say that the last patient will be screened within the coming months. The topline results are expected to be available during the last quarter of this year. As has been communicated before, a short recap of the study: we will include randomized patients in about 100 clinical sites across eight European countries. So, treatment time is eight weeks, and the primary endpoint is superiority to comparator in healing patients with severe GERD, which means LA grade C-D patients, at four weeks of treatment. And we have several key secondary endpoints, including healing and symptom relief, both at four and eight weeks of treatment, both in CD patients and in all patients. All patients. Referring to the LA grade A patients, and after the topline results from HEEALING 1 are available, we will then initiate the HEEALING 2 study, which will also include a maintenance study and involve patients in the U.S. So that was a short summary. HEEALING 1.

Christer Ahlberg
18:13 - 18:34

Okay. Let's go to the financials then. But thank you very much, Margit. It looks very promising, and everything is going according to plan when it comes to this important pivotal Phase III trial for us. So that's very good. Thank you. Magnus, please proceed with the financials. Sorry.

Magnus Christensen
18:35 - 22:32

Thank you. Christer. Yes. Here you can see the Q1 2026 financial highlights. And if we look at the cash balance. We ended the quarter with a cash balance of 476 million, compared with 487 at the end of 2025, giving us continued flexibility as we advance the HEEALING 1 study and prepare for the HEEALING 2 study. Total cash flow for the quarter was -12.7 million, compared with -42 million in the same period last year. As Christer mentioned, we received the first drawdown under the Claret Financing Agreement. Approximately 86 million before transaction costs, which supported the quarter's overall cash flow. R&D remained a clear driver of our cost base at 91% of operating expenses, and R&D expenses were 91 million in the quarter, compared with 38 million last year, reflecting the ongoing Phase III study as patients are recruited and screened, as Margit just mentioned. Operating loss for the quarter was nearly 91 million, compared with 47 million in Q1 last year. The increase reflects the high activity level in the Phase III program. At the end of the quarter, we had 22 PhDs, and in total, 17 employees and 27 consultants were affiliated with the company at the period end. Overall, our first quarter reflects focused investment in the Phase III execution, together with the added financial flexibility from the declared facility. And if we move to slide 12 here, you can see the financial overview year to year. And if you look at the net sales, they amounted to 10 million compared with zero. Last year, the revenue consisted partly of the license income from the Zentiva partnership in Europe and partly of other revenue. Revenue from Sinorda in China. Operating expenses increased year to year to around 100 million, and are driven primarily by the higher R&D spending. As the Phase III program moved into active execution phase. Administrative expenses also increased modestly, mainly due to consultancy fees and higher rental costs following the move to new premises. As we mentioned before, net loss for the quarter was around 88.8 million, compared with 43.7 million last year. And if we finally look at the balance sheet, as I mentioned, the cash at the end of the period was 476 million. Equity at the end of the period was 281 million, compared with 369 million at the end of 2025. Liabilities for the quarter reflected both the ongoing prioritisation of the upfront payment and the first tranche on the financing facility. Current liabilities increased mainly due to interest-bearing liabilities of almost 46 million and convertibles and warrants of 33 million arising from debt financing. Overall, our financial position remains aligned with our Phase III execution plan. And after the first tranche drawn down, we estimate the current working capital is sufficient into the third quarter of 2027 according to a current plan. Assumptions. And with that, I will hand back over to Christer.

Christer Ahlberg
22:34 - 23:20

Okay. Thank you. Magnus. Thank you. This brings us to the end of our formal remarks before we open for the line for questions. A few important dates ahead. Our annual general meeting will be held on May 21st, and we will report the second quarter on August 19th and the third quarter on November 11th. And of course, we will keep you updated on our Phase III study. Expected topline results in the fourth quarter. Exciting times. So potential key value inflection point. And then in the last quarter of this year. So with that, I would like to open the line for questions. Operator. Please go ahead.

Operator
23:21 - 23:43

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from George Burke from ABG Sundal Collier. Please go ahead.

George Burke
23:47 - 24:20

Hi, this is George from ABG calling. Thank you for taking my questions. I have two, please. Firstly, are you able to provide some guidance on how OpEx is expected to develop over the remainder of the year, perhaps using Q1 as a reference point? Secondly, I'm curious whether you could say a few words about the recent somewhat unusual block sale of shares conducted by one of your former board members. Thank you.

Christer Ahlberg
24:21 - 26:29

Okay. Thank you, George, for your questions. Normally, we do not guide on future-looking costs. But what we have said is, of course, that we have cash now, with current activities, into Q3 2027. And as you know, most of the cash is going to the Phase III trial, which is now ongoing at full speed. And that, of course, is costly. But, of course, at the end of the period, the cost level will go down, but it will be cost-intensive for the next quarters as well. But as I said, our estimate is that we have a good cash position into Q3 2027. The next question you had was regarding one of the major shareholders, or one of the founders. He's 75 years old and retired from the board in December. and the last year, and has no. As such, no involvement in or visibility into the company's operations anymore. We were also surprised by the transaction and how it was handled, but he has not given any formal statement related to the sale. But the company has no reason to believe that he has another motive than to diversify his personal financial exposures. So, there is nothing new in the company. And as you have seen, the Phase III trial looks very promising. And everything goes in the right direction as we wanted for the company. So it was a big surprise for us. It was for us. Unfortunately.

George Burke
26:29 - 26:31

Great. Thank you very much for answering my questions.

Christer Ahlberg
26:38 - 26:40

And other questions?

Operator
26:40 - 26:45

The next question comes from Arvid NE Kadar from NB Carnegie. Please go ahead.

Arvid NE Kadar
26:47 - 27:33

Hi. Good morning and thanks for taking my questions. So the first one on enrollment with about 85% of patients screened, but only about two thirds randomized. Is this an expected timing lag between screening and randomization? Or does it represent a higher than expected screening failure rate. And if so, should we read anything into this in terms of timelines or the final study population? And then secondly, on the Tegoprazan data at DDW. Now that we have the final or the full data set, how do you expect this to influence competitive dynamics across the PCAB drug class? Those are my questions. Thanks.

Christer Ahlberg
27:33 - 32:46

Okay, good. Thank you for that question. Thank you for these questions. Firstly, I can say that this screen failure rate is according to plan, approximately 50%. So that is just what we have expected. And there is, of course, the screening period is more than four weeks. So that's also a delay in that, not a delay, but that is how the procedure works. Always when it comes to studies like this, this is a big study. It's a little bit slow in the beginning. And the last month, the pace is increasing significantly. If you have done your work as you should. So the pace of screening is now at all-time high levels. That is the reason I would say that we are screening at a very high pace in most of the sites right now. And therefore, since there are approximately four weeks between screening and randomization. So that is the outcome of that. So nothing to. Nothing to worry about. It's exactly according to what we have seen and what we have planned. And that's actually, I would say, very good. We are following our plans. And that is, of course, something that pleased me. This is very good performance from my team here. So, and then when it comes to the other question regarding Tegoprazan, as you might have seen, they published and announced their results last week during the DDW in Chicago. And we were there, of course, and learned a lot. And what you could see is that this is perfectly in line with what we could estimate before we saw the results; given their acid control was a little bit lower than Vonoprazan, we should not have expected any other result than the one we now see, with a little bit more than 80% of the C and D patients in eight weeks, which is totally in line with what I showed you before. According to the biomarker and the correlation between healthy control and healing. And it also seems that they have a little bit faster onset compared to Vonoprazan. That's also what we have seen before in the control curves from them. So it's perfectly in accordance with our plan on how to differentiate ourselves versus the first-generation PCABs. And we, with 96%, now have a great chance to deliver best-in-class results. So both in acid control, but also in healing and in symptom relief. And that is what we will see now, hopefully then in the Phase III trial coming up at the end of the year. And when we listen to and discuss this with our key opinion leaders and the market, there is a good chance that we can deliver that. And of course, that will be seen as a clinical differentiation. Relevant differentiation and position for our product. And that is very promising for the future. And we are also looking into the market dynamics. Now, with two PCABs, Tegoprazan is not yet launched but will most likely launch next year in 2027. But I think that's good for the class and for the market, because then there are two players talking about PCABs instead of one player talking about Vonoprazan. So now we're going to discuss the class instead of the unique substances. And that's good for us. It's good preparation for us coming out as a best-in-class drug and gives us good opportunity also to target high PCAB users as well in the U.S. And that's of course good for us coming in as number three in the US. But it's also good to see that we definitely still have the chance to be first in Europe with the best-in-class potential here as well. So that just supports what we have said before.

Arvid NE Kadar
32:50 - 32:53

Great. Thank you for that. I'll jump back in.

Christer Ahlberg
32:56 - 32:59

Okay. Anything else? Any other questions.

Operator
32:59 - 33:13

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Joseph Haydn from WR securities. Please go ahead.

Joseph Haydn
33:16 - 33:46

Good morning, and thanks for taking my question. So with the financing agreement with Claret in place and the ability to streamline and speed up the start of your second Phase III trial, achieving positive results from HEEALING 1. What kind of timelines could you be looking at for the second pivotal study in terms of start the study and potential timeline to results. Thank you.

Christer Ahlberg
33:48 - 35:11

If we now look at what we have said, we can start preparing HEEALING 2 now and do that in parallel. And the more you can do that, normally, it's from the timing of the signing of the HEEALING 2 study before having the first patient in the trial; it's normally 6 to 8 months or something like that. And of course, that period is not for free. And the more we advance, the sooner we can start. But in any case, our. Our intention is to start this in next year. And the more we can work on it now, the sooner we can initiate it. And of course, we are also a little bit dependent on the results of the HEEALING 1 study as well. So we would like to see that and have the full report from that before starting up everything. So we can actually gain from that information when we finalize the HEEALING 2 study. Did that answer your question?

Joseph Haydn
35:14 - 35:16

Yes, sure. Thanks very much.

Christer Ahlberg
35:19 - 35:41

But also, yes, we will come back more on the timings on HEEALING 2 later, directly, either before or after the readout of Phase III HEEALING 1. So you will learn much more about that in the next coming months and year. So.

Operator
35:44 - 35:51

There are no more questions at this time. So I hand the conference back to the speakers for any written questions or closing comments.

Christer Ahlberg
35:56 - 38:27

Okay. I'm also looking if we have any written questions here. There are some questions regarding the sales from a founder, but I think I've already responded to that. And then also regarding the Claret deal. What we have said is that. I mean, the Claret. I mean, what we can see on the tranches there is that we have four different tranches when it comes to Claret. And that's the intention with that is that the tranches should be used when we have had value inflection points according to our development steps. And tranche B and C are in total 8 million. And tranche C is conditioned upon positive top line data from HEEALING 1 and tranche B. Could, of course, be, and also the second, the last Tranche D is also dependent on a condition. This is conditioned upon positive top-line results of the HEEALING 2. So, definitely very much supporting and aligned with the development steps. And the difference between B and C is that the tranche B is a convertible loan and the tranche C is a term loan. So that's the difference. Okay. I think we stop there if there are no other questions. And I wish you a great day and I hope to stay in touch and come back with more information regarding the HEEALING 1 study in the relatively near future. Thank you very much for your interest in Cinclus Pharma, and have a nice day. Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…